Many studies have investigated CD74 as a biomarker of ICB response in melanoma; additionally, it shows promise for other cancers, including triple-negative breast cancer [17], although there is a paucity of studies exploring its utility in these cases. Here, CD74 is linked to triple-negative breast carcinoma.